<sup>177</sup> Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II StudyAmar U. Kishan, Jérémie Calais, Michael Lauria et al.|Journal of Clinical Oncology|2025Cited by 24
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysisAmar U Kishan, Daniel E Spratt, Yilun Sun et al.|The Lancet|2026Cited by 5
Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancerJohn Nikitas, Luca Valle, Amar U. Kishan et al.|World Journal of Urology|2024Cited by 2
Dosimetric Comparison of Magnetic Resonance Imaging Guided Versus Reduced Margin Computed Tomography Guided Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Post Hoc Analysis of a Phase 3 TrialP.T. Courtney, Hui‐Ming Dong, Yi Lao et al.|International Journal of Radiation Oncology*Biology*Physics|2025Cited by 1
4644 Genomic and Transcriptomic Analysis of Radiorecurrent Prostate CancerBeth K. Neilsen, Amar U. Kishan, Rong Rong Huang et al.|Radiotherapy and Oncology|2025Cited by 0